Sustained Virological and Histological Response with Pretransplant Interferon Therapy in Renal Transplant Patients with Chronic Viral Hepatitis C
Patients who are anti-HCV positive before renal transplantation (Tx) have a significantly increased risk of posttransplant liver disease. We conducted a prospective, controlled study to evaluate the posttransplant outcome of renal graft candidates with HCV-associated chronic hepatitis (n = 30). Pati...
Gespeichert in:
| Veröffentlicht in: | American journal of nephrology 2001-11, Vol.21 (6), p.435-440 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 440 |
|---|---|
| container_issue | 6 |
| container_start_page | 435 |
| container_title | American journal of nephrology |
| container_volume | 21 |
| creator | Huraib, Sameer Iqbal, Aamir Tanimu, Danlami Abdullah, Abdulkader |
| description | Patients who are anti-HCV positive before renal transplantation (Tx) have a significantly increased risk of posttransplant liver disease. We conducted a prospective, controlled study to evaluate the posttransplant outcome of renal graft candidates with HCV-associated chronic hepatitis (n = 30). Patients were randomly assigned to either of two groups. All patients on enrollment underwent liver biopsy, which showed mild-to-moderate hepatitis activity (mean 4.1, range 2–6). Half the patients received interferon-alpha (IFN-a) administered at a dosage of 3 million units three times weekly for 1 year. Liver biopsy was repeated for treated patients at the end of IFN-a treatment. Of these, 11 patients received renal transplant (group A). The other half did not receive IFN-a and to date 10 patients have been transplanted (group B). Renal transplant recipients were prospectively followed for a period of 12 months and a follow-up liver biopsy was also done at the end of this period (end of study). Biochemical and virological responses were evaluated and the histologic activity index (HAI) scoring according to Knodell was assessed. The mean pretreatment serum HCV RNA level was 1.14 ± 0.84 and 1.0 ± 0.89 mEq/ml for groups A and B, respectively (bDNA assay sensitivity threshold is |
| doi_str_mv | 10.1159/000046646 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pasca</sourceid><recordid>TN_cdi_proquest_miscellaneous_72404920</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>107731468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-1a6b0648e11c6bddfe098a15cd27f44a55bc97db55eacebed00c49cdc250b4513</originalsourceid><addsrcrecordid>eNqF0VFrFDEQAOAgir22PvgsyFJQ8GHrZDfJbh7Lob1K0aKnr0s2me2l7mW3SZbSn-E_buqddyCCeQlkvpkJM4S8pHBKKZfvIR0mBBNPyIyyguZSVPCUzKDgkNcg-QE5DOEGgBY1VM_JAaWVlAWXM_Lr2xSisg5N9sP6oR-urVZ9ppzJFjbE3cNXDOPgAmZ3Nq6yK4_RKxfGXrmYXbiIvkM_uGy5Qq_G-8y6lOFS3nLPrlS06GLYlJivkrf6sWtiCxxTNNqQzY_Js071AV9s7yPy_eOH5XyRX345v5ifXeaaURFzqkQLgtVIqRatMR2CrBXl2hRVx5jivNWyMi3nqDS2aAA0k9roNJOWcVoekbebuqMfbicMsVnboLFPf8VhCk1VMGCygP_CAiSFiosET_6CN8Pk0xSSKYVkoi7KhN5tkPZDCB67ZvR2rfx9Q6F53Gaz22ayr7cFp3aNZi-360vgzRaokLbUpWFrG_auZAwEr5N7tXE_lb9GvwN_2pz8M3r26fNv0IymKx8AVCq91A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>236946823</pqid></control><display><type>article</type><title>Sustained Virological and Histological Response with Pretransplant Interferon Therapy in Renal Transplant Patients with Chronic Viral Hepatitis C</title><source>MEDLINE</source><source>Karger Journals</source><creator>Huraib, Sameer ; Iqbal, Aamir ; Tanimu, Danlami ; Abdullah, Abdulkader</creator><creatorcontrib>Huraib, Sameer ; Iqbal, Aamir ; Tanimu, Danlami ; Abdullah, Abdulkader</creatorcontrib><description>Patients who are anti-HCV positive before renal transplantation (Tx) have a significantly increased risk of posttransplant liver disease. We conducted a prospective, controlled study to evaluate the posttransplant outcome of renal graft candidates with HCV-associated chronic hepatitis (n = 30). Patients were randomly assigned to either of two groups. All patients on enrollment underwent liver biopsy, which showed mild-to-moderate hepatitis activity (mean 4.1, range 2–6). Half the patients received interferon-alpha (IFN-a) administered at a dosage of 3 million units three times weekly for 1 year. Liver biopsy was repeated for treated patients at the end of IFN-a treatment. Of these, 11 patients received renal transplant (group A). The other half did not receive IFN-a and to date 10 patients have been transplanted (group B). Renal transplant recipients were prospectively followed for a period of 12 months and a follow-up liver biopsy was also done at the end of this period (end of study). Biochemical and virological responses were evaluated and the histologic activity index (HAI) scoring according to Knodell was assessed. The mean pretreatment serum HCV RNA level was 1.14 ± 0.84 and 1.0 ± 0.89 mEq/ml for groups A and B, respectively (bDNA assay sensitivity threshold is <0.2 mEq/ml). HCV RNA became undetectable in 4 patients of group A. At the end of study period the mean quantitative HCV RNA titers were 1.43 ± 4.07 and 15.18 ± 11.08 mEq/ml in groups A and B, respectively (p < 0.0001). In group A, the mean HAI score decreased from 4.27 ± 1.19 to 1.64 ± 0.67 after IFN-a treatment (p < 0.0001). This score was maintained till the end of the study period with a mean of 1.82 ± 0.6. Mean HAI score of group B on enrollment was 3.9 ± 1.2 and at the end of study increased to 5.5 ± 1.35 (p = 0.01). There was statistically significant difference (p value less than 0.0001) between the HAI scores at the end of the study period between the two groups. These results demonstrate that interferon therapy while on dialysis is associated with less viremia and decreased progression of chronic liver disease in renal transplant patients with hepatitis C.</description><identifier>ISSN: 0250-8095</identifier><identifier>EISSN: 1421-9670</identifier><identifier>DOI: 10.1159/000046646</identifier><identifier>PMID: 11799259</identifier><identifier>CODEN: AJNED9</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Adult ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; Clinical Study ; Combined surgery. Multiple transplantations ; Drug Administration Schedule ; Female ; Hepatitis C virus ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - pathology ; Hepatitis C, Chronic - virology ; Humans ; Immunosuppressive Agents - administration & dosage ; Interferon-alpha - therapeutic use ; Kidney Failure, Chronic - therapy ; Kidney Transplantation ; Liver - pathology ; Male ; Medical sciences ; Preoperative Care ; Prospective Studies ; Renal Dialysis ; RNA, Viral - analysis ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Treatment Outcome</subject><ispartof>American journal of nephrology, 2001-11, Vol.21 (6), p.435-440</ispartof><rights>2001 S. Karger AG, Basel</rights><rights>2002 INIST-CNRS</rights><rights>Copyright 2001 S. Karger AG, Basel</rights><rights>Copyright S. Karger AG Nov/Dec 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-1a6b0648e11c6bddfe098a15cd27f44a55bc97db55eacebed00c49cdc250b4513</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13440658$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11799259$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huraib, Sameer</creatorcontrib><creatorcontrib>Iqbal, Aamir</creatorcontrib><creatorcontrib>Tanimu, Danlami</creatorcontrib><creatorcontrib>Abdullah, Abdulkader</creatorcontrib><title>Sustained Virological and Histological Response with Pretransplant Interferon Therapy in Renal Transplant Patients with Chronic Viral Hepatitis C</title><title>American journal of nephrology</title><addtitle>Am J Nephrol</addtitle><description>Patients who are anti-HCV positive before renal transplantation (Tx) have a significantly increased risk of posttransplant liver disease. We conducted a prospective, controlled study to evaluate the posttransplant outcome of renal graft candidates with HCV-associated chronic hepatitis (n = 30). Patients were randomly assigned to either of two groups. All patients on enrollment underwent liver biopsy, which showed mild-to-moderate hepatitis activity (mean 4.1, range 2–6). Half the patients received interferon-alpha (IFN-a) administered at a dosage of 3 million units three times weekly for 1 year. Liver biopsy was repeated for treated patients at the end of IFN-a treatment. Of these, 11 patients received renal transplant (group A). The other half did not receive IFN-a and to date 10 patients have been transplanted (group B). Renal transplant recipients were prospectively followed for a period of 12 months and a follow-up liver biopsy was also done at the end of this period (end of study). Biochemical and virological responses were evaluated and the histologic activity index (HAI) scoring according to Knodell was assessed. The mean pretreatment serum HCV RNA level was 1.14 ± 0.84 and 1.0 ± 0.89 mEq/ml for groups A and B, respectively (bDNA assay sensitivity threshold is <0.2 mEq/ml). HCV RNA became undetectable in 4 patients of group A. At the end of study period the mean quantitative HCV RNA titers were 1.43 ± 4.07 and 15.18 ± 11.08 mEq/ml in groups A and B, respectively (p < 0.0001). In group A, the mean HAI score decreased from 4.27 ± 1.19 to 1.64 ± 0.67 after IFN-a treatment (p < 0.0001). This score was maintained till the end of the study period with a mean of 1.82 ± 0.6. Mean HAI score of group B on enrollment was 3.9 ± 1.2 and at the end of study increased to 5.5 ± 1.35 (p = 0.01). There was statistically significant difference (p value less than 0.0001) between the HAI scores at the end of the study period between the two groups. These results demonstrate that interferon therapy while on dialysis is associated with less viremia and decreased progression of chronic liver disease in renal transplant patients with hepatitis C.</description><subject>Adult</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Clinical Study</subject><subject>Combined surgery. Multiple transplantations</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - pathology</subject><subject>Hepatitis C, Chronic - virology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Kidney Transplantation</subject><subject>Liver - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Preoperative Care</subject><subject>Prospective Studies</subject><subject>Renal Dialysis</subject><subject>RNA, Viral - analysis</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Treatment Outcome</subject><issn>0250-8095</issn><issn>1421-9670</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqF0VFrFDEQAOAgir22PvgsyFJQ8GHrZDfJbh7Lob1K0aKnr0s2me2l7mW3SZbSn-E_buqddyCCeQlkvpkJM4S8pHBKKZfvIR0mBBNPyIyyguZSVPCUzKDgkNcg-QE5DOEGgBY1VM_JAaWVlAWXM_Lr2xSisg5N9sP6oR-urVZ9ppzJFjbE3cNXDOPgAmZ3Nq6yK4_RKxfGXrmYXbiIvkM_uGy5Qq_G-8y6lOFS3nLPrlS06GLYlJivkrf6sWtiCxxTNNqQzY_Js071AV9s7yPy_eOH5XyRX345v5ifXeaaURFzqkQLgtVIqRatMR2CrBXl2hRVx5jivNWyMi3nqDS2aAA0k9roNJOWcVoekbebuqMfbicMsVnboLFPf8VhCk1VMGCygP_CAiSFiosET_6CN8Pk0xSSKYVkoi7KhN5tkPZDCB67ZvR2rfx9Q6F53Gaz22ayr7cFp3aNZi-360vgzRaokLbUpWFrG_auZAwEr5N7tXE_lb9GvwN_2pz8M3r26fNv0IymKx8AVCq91A</recordid><startdate>20011101</startdate><enddate>20011101</enddate><creator>Huraib, Sameer</creator><creator>Iqbal, Aamir</creator><creator>Tanimu, Danlami</creator><creator>Abdullah, Abdulkader</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7T5</scope><scope>7X8</scope></search><sort><creationdate>20011101</creationdate><title>Sustained Virological and Histological Response with Pretransplant Interferon Therapy in Renal Transplant Patients with Chronic Viral Hepatitis C</title><author>Huraib, Sameer ; Iqbal, Aamir ; Tanimu, Danlami ; Abdullah, Abdulkader</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-1a6b0648e11c6bddfe098a15cd27f44a55bc97db55eacebed00c49cdc250b4513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Clinical Study</topic><topic>Combined surgery. Multiple transplantations</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - pathology</topic><topic>Hepatitis C, Chronic - virology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Kidney Transplantation</topic><topic>Liver - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Preoperative Care</topic><topic>Prospective Studies</topic><topic>Renal Dialysis</topic><topic>RNA, Viral - analysis</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huraib, Sameer</creatorcontrib><creatorcontrib>Iqbal, Aamir</creatorcontrib><creatorcontrib>Tanimu, Danlami</creatorcontrib><creatorcontrib>Abdullah, Abdulkader</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>Immunology Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huraib, Sameer</au><au>Iqbal, Aamir</au><au>Tanimu, Danlami</au><au>Abdullah, Abdulkader</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sustained Virological and Histological Response with Pretransplant Interferon Therapy in Renal Transplant Patients with Chronic Viral Hepatitis C</atitle><jtitle>American journal of nephrology</jtitle><addtitle>Am J Nephrol</addtitle><date>2001-11-01</date><risdate>2001</risdate><volume>21</volume><issue>6</issue><spage>435</spage><epage>440</epage><pages>435-440</pages><issn>0250-8095</issn><eissn>1421-9670</eissn><coden>AJNED9</coden><abstract>Patients who are anti-HCV positive before renal transplantation (Tx) have a significantly increased risk of posttransplant liver disease. We conducted a prospective, controlled study to evaluate the posttransplant outcome of renal graft candidates with HCV-associated chronic hepatitis (n = 30). Patients were randomly assigned to either of two groups. All patients on enrollment underwent liver biopsy, which showed mild-to-moderate hepatitis activity (mean 4.1, range 2–6). Half the patients received interferon-alpha (IFN-a) administered at a dosage of 3 million units three times weekly for 1 year. Liver biopsy was repeated for treated patients at the end of IFN-a treatment. Of these, 11 patients received renal transplant (group A). The other half did not receive IFN-a and to date 10 patients have been transplanted (group B). Renal transplant recipients were prospectively followed for a period of 12 months and a follow-up liver biopsy was also done at the end of this period (end of study). Biochemical and virological responses were evaluated and the histologic activity index (HAI) scoring according to Knodell was assessed. The mean pretreatment serum HCV RNA level was 1.14 ± 0.84 and 1.0 ± 0.89 mEq/ml for groups A and B, respectively (bDNA assay sensitivity threshold is <0.2 mEq/ml). HCV RNA became undetectable in 4 patients of group A. At the end of study period the mean quantitative HCV RNA titers were 1.43 ± 4.07 and 15.18 ± 11.08 mEq/ml in groups A and B, respectively (p < 0.0001). In group A, the mean HAI score decreased from 4.27 ± 1.19 to 1.64 ± 0.67 after IFN-a treatment (p < 0.0001). This score was maintained till the end of the study period with a mean of 1.82 ± 0.6. Mean HAI score of group B on enrollment was 3.9 ± 1.2 and at the end of study increased to 5.5 ± 1.35 (p = 0.01). There was statistically significant difference (p value less than 0.0001) between the HAI scores at the end of the study period between the two groups. These results demonstrate that interferon therapy while on dialysis is associated with less viremia and decreased progression of chronic liver disease in renal transplant patients with hepatitis C.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>11799259</pmid><doi>10.1159/000046646</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-8095 |
| ispartof | American journal of nephrology, 2001-11, Vol.21 (6), p.435-440 |
| issn | 0250-8095 1421-9670 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72404920 |
| source | MEDLINE; Karger Journals |
| subjects | Adult Antiviral Agents - therapeutic use Biological and medical sciences Clinical Study Combined surgery. Multiple transplantations Drug Administration Schedule Female Hepatitis C virus Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - pathology Hepatitis C, Chronic - virology Humans Immunosuppressive Agents - administration & dosage Interferon-alpha - therapeutic use Kidney Failure, Chronic - therapy Kidney Transplantation Liver - pathology Male Medical sciences Preoperative Care Prospective Studies Renal Dialysis RNA, Viral - analysis Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Treatment Outcome |
| title | Sustained Virological and Histological Response with Pretransplant Interferon Therapy in Renal Transplant Patients with Chronic Viral Hepatitis C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A55%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sustained%20Virological%20and%20Histological%20Response%20with%20Pretransplant%20Interferon%20Therapy%20in%20Renal%20Transplant%20Patients%20with%20Chronic%20Viral%20Hepatitis%20C&rft.jtitle=American%20journal%20of%20nephrology&rft.au=Huraib,%20Sameer&rft.date=2001-11-01&rft.volume=21&rft.issue=6&rft.spage=435&rft.epage=440&rft.pages=435-440&rft.issn=0250-8095&rft.eissn=1421-9670&rft.coden=AJNED9&rft_id=info:doi/10.1159/000046646&rft_dat=%3Cproquest_pasca%3E107731468%3C/proquest_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=236946823&rft_id=info:pmid/11799259&rfr_iscdi=true |